Clinical trial
A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
NCT03311854 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 20, 2018
- Completion date
- May 19, 2020
- Enrollment
- 14 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
adult onset still disease, arthritis, juvenile, lymphohistiocytosis, hemophagocytic, macrophage activation syndrome